16
Participants
Start Date
September 30, 2009
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Dutasteride
Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
Placebo
The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
University of Colorado Hospital, Aurora
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Colorado, Denver
OTHER